Skip to content

Sylvie Alaux

5 papers in the library · 9 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

Psychiatry Research February 2, 2026 Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al. 1 citation

Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...

Effects of LSD and Psilocybin on Heart Rate in Patients Receiving Psychedelic Treatment for Depressive and Anxiety Disorders: A Retrospective Observational Study

Psychology International December 19, 2025 Morgan C H Cheng, Tatiana Aboulafia Brakha, Albert Buchard et al.

Classic psychedelics such as lysergic acid diethylamide (LSD) and psilocybin induce mild cardiovascular activation in addition to their psychological effects. While these effects are well described in healthy adults, little is known about their dynamics in clinical populations undergoing psychedelic-assisted psychotherapy. This retrospective, observational, single-center study analyzed...

Pilot Data on Salivary Oxytocin as a Biomarker of LSD Response in Patients with Major Depressive Disorder

Psychoactives August 1, 2025 L. Cazorla, Sylvie Alaux, Caroline Amberger et al.

Despite growing evidence supporting the efficacy of LSD-assisted psychotherapy in treating major depressive disorder (MDD), identifying reliable psychopharmacological biomarkers remains necessary. Oxytocin, a neuropeptide implicated in social bonding and flexibility, is a promising candidate due to its release following serotonergic psychedelic administration in healthy individuals; however,...

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

European Psychiatry April 1, 2025 L. Cazorla, Sylvie Alaux, Cédric Mabilais et al.

Introduction One of the main mechanisms of action of LSD in psychedelic-assisted psychotherapy (PAP) is the activation of 5HT2A receptors. This triggers a cascade of neurochemical processes with the release of neurotransmitters and neurohormonal substances. The release of oxytocin in this process is well documented in pre-clinical studies, with recent evidence in healthy subjects. We have no...

Psychothérapie assistée par psychédéliques (PAP) : le modèle genevois

Annales Médico-psychologiques revue psychiatrique July 10, 2024 Federico Seragnoli, Gabriel Thorens, Louise Penzenstadler et al. 8 citations

Dans cet article, nous avons pour objectif de décrire un modèle interdisciplinaire de psychothérapie assistée par psychédéliques (PAP) que nous avons développé dans un cadre institutionnel aux hôpitaux universitaires de Genève. La psychothérapie assistée par psychédéliques (PAP) est une approche psychothérapeutique exploitant l’altération de l’état de conscience induite par une substance...